Benchmark Starts Canopy Growth Corp (CGC) at Buy

(Updated - September 25, 2018 8:11 AM EDT)

(updated to add analyst comment)

Benchmark analyst Mike Hickey initiates coverage on Canopy Growth Corp (NYSE: CGC) with a Buy rating.

The analyst puts his price target at CAD$100.00.

Hickey offers four reasons for his positive view:

1. Canopy’s early leadership in the medical cannabis market in Canada,

2. upcoming legalization of recreational cannabis in Canada,

3. international growth from countries that have legalized cannabis and likely future legalization of cannabis for medical and recreational use in the US and overseas, and

4. meaningful investment from Constellation Brands, which accelerates the ongoing build-out of its international production and distribution operations and domestic retail infrastructure to meet rapidly growing global demand, and which enables M&A opportunities and internal development of new brands and products that use cannabis as an active ingredient.

Further he believes the international opportunity for the company "is enormous" as the global market could reach upwards of CAD$285 billion in the coming 15 years. He also calls the Constellation Brands investment "a game changer."

For an analyst ratings summary and ratings history on Canopy Growth Corp click here. For more ratings news on Canopy Growth Corp click here.

Shares of Canopy Growth Corp closed at $52.11 yesterday.

You May Also Be Interested In

• Britvic Plc. (BVIC:LN) (BTVCY) PT Raised to GBP9.30 at Goldman Sachs
• Insurance Australia Group Ltd. (IAG:AU) (IAUGD) PT Lowered to AUD5.41 at Goldman Sachs
• Hindustan Unilever Ltd (HUVR:IN) PT Raised to INR2,800 at Macquarie